LENEXA, Kan., Oct. 2, 2024 /PRNewswire/ -- Ambetter from Sunflower Health Plan, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Kansans in 91 counties in plan year 2025. Open enrollment for the Health Insurance Marketplace for Kansas runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
"We believe everyone should have the benefits, tools and coverage they need to take charge of their health," said Michael Stephens, plan president and chief executive officer, Sunflower Health Plan. "Ambetter from Sunflower Health Plan has been equipping Kansans with affordable plans to proactively manage their wellness since 2018."
Ambetter from Sunflower Health Plan offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is a full list of the 91 counties in which Ambetter from Sunflower Health Plan will be offered in 2025:
Kansas residents interested in learning more about Ambetter from Sunflower Health Plan or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/ks.
About Ambetter from Sunflower Health Plan
Ambetter from Sunflower Health Plan serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter from Sunflower Health Plan is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in Kansas. For more information, visit ambetterhealth.com/en/ks. This is a solicitation for insurance. For information on your right to receive an Ambetter from Sunflower Health Plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$60.37 |
Daily Change: | 0.02 0.03 |
Daily Volume: | 3,998,309 |
Market Cap: | US$30.480B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB